Analyzing Responses to 177LuPSMA-617 in Patients With Metastatic CRPC

Video

Jeremie Calais, MD, discusses the results from a preliminary analysis of a phase II trial investigating 177 lutetium prostate-specific membrane antigen-617 in patients with metastatic castration-resistant prostate cancer.

Jeremie Calais, MD, assistant clinical professor, Department of Nuclear Medicine, Ahmanson Translational Imaging Division, discusses the results from a preliminary analysis ofa phase II trial investigating 177 lutetium prostate-specific membrane antigen-617(177LuPSMA-617) in patients with metastatic castration-resistant prostate cancer.

Prostate-specific antigen (PSA) levels, which was the primary endpoint of the study, declined by at least 50% after 2 cycles of therapy. This seems early, Calais says, but the retrospective analysis data appeared promising.

Related Videos
Video 8 - "Clinical Pearls for Optimal Management of mHSPC"
Video 7 - "Multidisciplinary Approach in mHSPC Management "
Video 6 - "Treatment Considerations in High Disease Burden and Comorbidities"
Video 5 - "Pivotal Trials in mHSPC"
Video 4 - "ARASENS Trial- Darolutamide in mHSPC"
Video 3 - "Treatment Intensification in Metastatic Prostate Cancer"
Video 2 - "Treatment Options for mHSPC"
Video 1 - "Initial Impression and Risk Assessment"
Related Content
Skin Cancer Awareness Month: Sun Safety and Tackling Diagnosis

Skin Cancer Awareness Month: Sun Safety and Tackling Diagnosis

May 15th 2024
Article

For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.

Read More

Dizman’s Global Pursuit to Cancer Research and Understanding

Dizman’s Global Pursuit to Cancer Research and Understanding

April 1st 2024
Podcast

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Listen

Expanding 177Lutetium-PSMA-617 Use in the Community

Expanding 177Lutetium-PSMA-617 Use in the Community

May 12th 2024
Article

Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.

Read More

A Deep Dive Into the Evolving Landscape of Prostate Cancer

A Deep Dive Into the Evolving Landscape of Prostate Cancer

January 15th 2024
Podcast

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

Listen

CAPTURE Trial Reveals BRCA Mutations Linked to Worse Outcomes in mCRPC

CAPTURE Trial Reveals BRCA Mutations Linked to Worse Outcomes in mCRPC

May 10th 2024
Article

Those with metastatic castration-resistant prostate cancer in the BRCA subgroup experienced worse outcomes vs those in non-BRCA subgroups, according to the results of the CAPTURE trial.

Read More

Advancing Care in Urothelial Carcinoma With the MAIN-CAV Trial

Advancing Care in Urothelial Carcinoma With the MAIN-CAV Trial

May 9th 2024
Article

In an interview with Targeted Oncology, Shilpa Gupta, MD, discussed the rationale and potential significance of the MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma.

Read More